Comparison of Monoclonal Antibodies in Ovarian Cancer
Author Information
Author(s): C.F.M. Molthoff, H.M. Pinedo, H.M.M. Schliiper, H.W. Nijman, E. Boven
Primary Institution: Free University Hospital, Amsterdam, The Netherlands
Hypothesis
How do the pharmacokinetics and biodistribution of monoclonal antibodies OC125, OV-TL 3, and 139H2 compare in experimental ovarian cancer?
Conclusion
MAb OV-TL 3 showed the most favorable tumor localization among the tested monoclonal antibodies.
Supporting Evidence
- MAb 139H2 localized specifically in ovarian cancer xenografts.
- MAb OV-TL 3 showed the highest tumor uptake at 17.7%.
- Binding characteristics were assessed using the OVCAR-3 cell line.
- F(ab')2 fragments had lower radiation doses to tumors compared to IgG.
- Immunoperoxidase staining showed heterogeneous binding for MAbs OC125 and 139H2.
Takeaway
This study looked at how well different antibodies can find and stick to ovarian cancer cells in mice. One antibody did a better job than the others.
Methodology
The study compared the binding characteristics, pharmacokinetics, biodistribution, and dosimetry of three monoclonal antibodies in nude mice with ovarian cancer xenografts.
Potential Biases
Potential cross-reactivity of MAb OV-TL 3 with human white blood cells could affect its clinical use.
Limitations
The study was conducted in mice, which may not fully predict human responses.
Participant Demographics
Nude mice bearing OVCAR-3 xenografts were used in the study.
Want to read the original?
Access the complete publication on the publisher's website